Knight Therapeutics Inc.
TSX : GUD

Knight Therapeutics Inc.

May 31, 2016 08:00 ET

Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City

MONTREAL, QUEBEC--(Marketwired - May 31, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President and CEO, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 1, 2016 at 2:00 pm ET at the Hotel Le Crystal in Montreal, while Jeffrey Kadanoff, CFO, is scheduled to present a corporate update at the Jefferies Healthcare Conference on Thursday, June 9, 2016 at 9:30 am ET at the Grand Hyatt New York. A copy of the Jefferies Healthcare Conference presentation will be available at www.gud-knight.com.

About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Contact Information